Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck product Intangible Asset Carrying Value — Adempas (riociguat) ($M) ($M)
Form 10-Q / 10-K Goodwill and Other Intangibles Note
Latest, Q2 2026
203
Period ended Jun 30, 2026
Change on a year earlier
-41.7%
348 in Q2 2025
History
31 quarters
Since Q4 2017
Sources
31
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Product Intangible Asset Carrying Value — Adempas (riociguat) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 203 | -41.7% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 239 | -32.3% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 280 | -24.7% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 312 | -27.6% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 348 | -21.8% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 353 | – | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 372 | – | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 431 | -19.1% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 445 | -24.1% | Form 10-Q (filed 2024-08-05) ↗ |
| Q3 2023 | Sep 30, 2023 | 533 | -10.7% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 586 | -15.2% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 613 | -19.1% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 633 | -21.5% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2022 | Sep 30, 2022 | 597 | -31.3% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 691 | -24.9% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 758 | -19.9% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 806 | -5.1% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 869 | +3.7% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 920 | +10.6% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 946 | +12.1% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 849 | -3.9% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 838 | -6.2% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 832 | -13.0% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 844 | -13.6% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 883 | -11.7% | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2019 | Sep 30, 2019 | 893 | -18.8% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 956 | – | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 977 | – | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,000 | +11.9% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,100 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q4 2017 | Dec 31, 2017 | 894 | – | Form 10-K (filed 2018-02-27) ↗ |
Cite this data
StockData. (2026). Merck Product Intangible Asset Carrying Value — Adempas (riociguat) ($M) ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/intang_drug_adempas
See every metric in the Merck KPI table. Data updated Oct 26, 2026.